Multi-Blend Withdrawal Composition to Reduce Opioid Cravings
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for opioid withdrawal syndrome (OWS) are inadequate in addressing the severe symptoms and cravings associated with opioid discontinuation, leading to a significant barrier in opioid cessation and OUD treatment, with a need for novel therapeutic strategies to target and minimize these symptoms.
Innovation Solution
A composition comprising cannabidiol (CBD), cannabigerol (CBG), gamma aminobutyric acid (GABA), Inositol, Vitamin B-12, calcium, magnesium, potassium citrate, L-glutamine, turmeric, green tea, passion fruit, 5-hydroxy-L-Tryptophan, N-acetyl L-Tyrosine, and L-Phenylalanine, formulated to alleviate anxiety, inflammation, and neurotransmitter imbalances during opioid withdrawal.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional opioid cessation methods are used, then opioid discontinuation is achieved, but severe withdrawal symptoms and cravings occur
Solution Approach 1:
The patent introduces a multi-component composition as an intermediary substance that mediates the withdrawal process. The composition includes CBD (cannabidiol) as a primary active ingredient along with CBG (cannabigerol), GABA (gamma-aminobutyric acid), inositol, vitamin B12, and various amino acids. These substances act as mediators between the opioid system and the withdrawal state, reducing the severity of withdrawal symptoms while facilitating successful opioid discontinuation. The intermediary composition addresses multiple withdrawal symptoms simultaneously through its multi-component formulation.
2Stability of the object's composition
If opioid use is prolonged to maintain normal feelings, then tolerance and physical dependence develop, but the user experiences worsened pain and reduced drug effects
Solution Approach 1:
The patent converts the harmful effects of opioid withdrawal into a beneficial treatment opportunity. By using CBD and related compounds, the severe withdrawal symptoms that normally deter cessation are transformed into a manageable process. The composition leverages the body's endocannabinoid system and other physiological pathways to convert the harmful withdrawal experience into a beneficial cessation process, reducing symptoms while maintaining the goal of opioid discontinuation.
3Power
If higher doses of opioids are consumed to overcome tolerance, then the desired effect is temporarily achieved, but dependence and addiction worsen
Solution Approach 1:
The patent employs a temporary, short-term intervention using the composition during the withdrawal period. The CBD-based composition is used as a disposable solution for the duration of withdrawal symptoms, typically a limited time frame, after which the goal is complete opioid cessation. This approach provides sufficient relief during the critical withdrawal period without creating long-term dependence, as the composition itself does not produce the same addictive effects as traditional opioids.
Data Source
AI summary
A composition which provides a comprehensive solution for curbing, moderating and/or reducing the symptoms and cravings of opioid withdrawal syndrome. The composition is provided in the form of a capsule, pill, liquid, powder for mixing, or patch. In accordance with embodiments of the invention a composition for treating opioid withdrawal syndrome is provided. The composition includes (i) a therapeutically effective amount of a functional blend comprising a mixture of cannabidiol, cannabigerol, gamma aminobutyric acid, Inositol, and Vitamin B-12; (ii) a therapeutically effective amount of a hydration blend comprising a mixture of calcium, magnesium, potassium citrate, and L-glutamine; (iii) a therapeutically effective amount of an anti-inflammatory blend comprising a mixture of turmeric, green tea, and passion fruit; and (iv) a therapeutically effective amount of a neurotransmitter blend comprising 5-hydroxy-L-Tryptophan, N-acetyl L-Tyrosine, and L-Phenylalanine. The composition is consummate addition to a complete opioid cessation and withdrawal program because it targets, moderates, curbs and/or ameliorates the deleterious symptoms of opioid cessation and withdrawal. The composition is consummate addition to a complete opioid cessation and withdrawal program because it targets, moderates, curbs and/or ameliorates the potentially incessant drug cravings and the associated anxiety and stress.